Actively Recruiting
Effectiveness and Cost-Effectiveness Evaluations of AI-Assisted Diagnostic Software (VeriSee) for Ophthalmic Disease Screening
Led by National Taiwan University Hospital · Updated on 2025-06-22
1000
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
N
National Taiwan University Hospital
Lead Sponsor
F
Fu Jen Catholic University Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating the effectiveness of an artificial intelligence (AI)-assisted screening system called VeriSee in diagnosing common eye diseases, including age-related macular degeneration (AMD) and diabetic retinopathy (DR). The study aims to provide scientific evidence on how this AI system could improve the efficiency and accuracy of ophthalmic disease diagnosis and treatment by supporting ophthalmologists in clinical decisions. Participants will undergo fundus photography screening where the VeriSee AI-assisted diagnostic software analyzes the images to detect signs of AMD and DR. Ophthalmologists will also independently interpret the same images, and their findings will be compared with the AI's results. The VeriSee system is installed on a computer and uses advanced AI algorithms to assess image quality and disease conditions, providing instant diagnostic support in clinical settings. During the study, participants' fundus images and clinical data will be collected and analyzed. Researchers will measure the sensitivity, specificity, and agreement between AI-assisted screening and physician-confirmed diagnoses over about one month. Cost analysis including direct and indirect expenses will be evaluated up to 12 months after screening. The study spans from enrollment through follow-up, with the goal of improving early detection and management of these eye conditions.
CONDITIONS
Brief Title
Effectiveness and Cost-Effectiveness Evaluations of AI-Assisted Diagnostic Software (VeriSee) for Ophthalmic Disease Screening
Who Can Participate
Eligibility Criteria
You may qualify if you...
- VeriSee AMD is used in non-retinal subspecialty ophthalmology clinics for adults aged 50 and above.
- VeriSee DR is used in non-retinal subspecialty clinics for diabetic patients aged 20 and above.
You will not qualify if you...
- The patient does not agree to participate in the trial or is unable to provide informed consent.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Approximately 1 month
Participants undergo fundus photography screening using AI-assisted diagnostic software and ophthalmologists independently interpret the same images to compare results.
1 visit (in-person)
Duration - 12 months
Participants' health and outcomes are monitored for up to 12 months following screening to assess cost-effectiveness and clinical outcomes.
Trial Site Locations
Total: 1 location
1
National Taiwan University Hospital
Taipei, Taiwan, Taiwan, 100225
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
SCREENING
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here